Relationship Between Acute Severe Pancreatitis and Mitochondrial DNA

NCT04079777 | Unknown DMC

• 1 other identifier: severe acute pancreatitis
• Study Type: observational
• Target: 50
• Locations: 1 country
• Sites: 1

Brief Summary

Plasma mtDNA analysis aids in predicting pancreatic necrosis in severe acute pancreatitis patients.After the onset of severe acute pancreatitis, pancreatic necrosis and the content of mtDNA in plasma will increase, showing a significant positive correlation.

Conditions

Severe Acute Pancreatitis

Keywords

Mitochondrial DNA ;mtDNA;; Acute pancreatitis;SAP;severe acute pancreatitis;; Acute pancreatic necrosis;; Inflammatory necrosis;

Outcome Measures

Primary Outcomes (1)

• mtDNA

  mtDNA content In plasma

  one day after onset to clinical cure

Study Arms (2)

Clinical diagnosis of severe acute pancreatitis

1, with typical clinical manifestations, such as abdominal pain or nausea and vomiting, accompanied by epigastric tenderness or peritoneal irritation. 2\. Pancreatin content in serum, urine or abdominal cavity puncture fluid increases. 3\. Image examination (ultrasound, CT) showed pancreatic inflammation or pancreatic inflammation seen by surgery or confirmed by autopsy pathology. 4, can except other similar clinical manifestations of lesions.

Drug: Clinical treatment

mtDNA

Mitochondrial DNA is the genetic material in mitochondria. Mitochondria can produce energy (ATP) for cells, which is a special form of ribonucleic acid found in mitochondria of cells. Mitochondria are organelles that provide energy (ATP) to cells. There are usually many DNA molecules in a mitochondria. They carry their own DNA--mtDNA, and mutations in these genes can cause mitochondrial diseases. Although the symptoms of the disease are changeable, organs that consume more energy, such as brain, muscle and heart, are usually affected. Since mitochondria are transmitted through egg cells, related diseases will be inherited from the mother.

Drug: Clinical treatment

Interventions

Clinical treatment DRUG

Liquid Resuscitation, Anti-infection

Also known as: Clinical treatment such as fluid infusion

Clinical diagnosis of severe acute pancreatitis; mtDNA

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Acute severe pancreatitis patients admitted to hospital emergency department

You may qualify if:

• Clinical diagnosis of severe acute pancreatitis
• Admission time less than two days

You may not qualify if:

• Malignant Tumor
• Positive confirmed pregnancy or urinary pregnancy test
• Acute liver failure
• Immunosuppressive state
• Hormone use
• Transplantation
• Death within seven days
• Blood transfusion over 1000ml in seven days
• Missing Visits
• Incomplete information
• Family Requirements

Sponsors & Collaborators

• First People's Hospital of Chenzhou: lead

Study Sites (1)

The First Hospital of Chenzhou

Chenzhou, Hunan, 450003, China

Location

MeSH Terms

Conditions

Pancreatitis

Condition Hierarchy (Ancestors)

Pancreatic Diseases; Digestive System Diseases

Study Officials

• Dixian DX

  First People's Hospital of Chenzhou

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: PROSPECTIVE
• Target Duration: 90 Days
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Critical Care Medicine

Study Record Dates

• First Submitted: August 30, 2019
• First Posted: September 6, 2019
• Study Start: July 1, 2018
• Primary Completion: December 1, 2019
• Study Completion: June 1, 2020
• Last Updated: September 6, 2019

Record last verified: 2019-09

Locations

CN (1)